Map1Lc3B2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| MAP1LC3B2 Protein |
|---|
| Protein Name | LC3B2 (Microtubule-Associated Protein 1 Light Chain 3 Beta 2) |
| Gene | MAP1LC3B2 |
| UniProt ID | Q9GQL5 |
| PDB ID | 2K6R, 2L7Q |
| Molecular Weight | 14.9 kDa (16.5 kDa lipidated) |
| Subcellular Localization | Cytoplasm, Autophagosome, Lysosome |
| Protein Family | ATG8 family, MAP1 LC3 family |
| Chromosomal Location | 12p12.1 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Stroke |
MAP1LC3B2 (LC3B2) is a paralog of the well-characterized LC3B (MAP1LC3B) involved in autophagosome formation and selective autophagy. As a member of the ATG8 family, LC3B2 plays critical roles in neuronal autophagy, protein aggregate clearance, and cellular homeostasis in the brain.
LC3B2 is expressed primarily in testis and at lower levels in brain tissue, where it participates in the autophagy-lysosomal pathway. The protein undergoes post-translational lipidation (phosphatidylethanolamine conjugation) similar to other ATG8 family members, enabling its incorporation into autophagosomal membranes.
¶ Domain Architecture
| Domain |
Position |
Function |
| Ubiquitin-like fold |
1-120 |
Core ATG8 structure |
| N-terminal region |
1-28 |
Membrane interaction |
| LIR (LC3-Interacting Region) docking site |
13-16 |
Autophagy receptor binding |
| Phosphatidylethanolamine binding |
114-120 |
Membrane anchoring |
| GABARAP interaction region |
Various |
Protein-protein interactions |
- Ubiquitin-like fold: Similar to ubiquitin, ~40% identical
- Hydrophobic patches: Interaction surfaces
- N-terminal glycine: Required for lipidation
- Conserved residues: Essential for ATG7 and ATG3 interactions
- Proteolytic processing: ATG4 cleaves N-terminal arginine
- Lipidation: ATG7 (E1), ATG3 (E2) mediate PE conjugation
- Phosphorylation: Various kinases regulate activity
LC3B2 expression in the brain:
- Neurons: Moderate expression in pyramidal neurons
- Astrocytes: Lower expression
- Microglia: Constitutive expression
- Oligodendrocytes: Myelination-related expression
- Testis: Highest expression
- Brain: Moderate expression
- Heart, liver, kidney: Lower levels
- Developmental regulation: Increases with age
LC3B2 participates in:
- Initiation: Recruitment to phagophore
- Expansion: Membrane recruitment and expansion
- Closure: Autophagosome completion
- Fusion: Interaction with lysosomes
LC3B2 recognizes:
- Aggregate-prone proteins: Huntingtin, α-synuclein, tau
- Damaged organelles: Mitochondria, ER
- Pathogens: Invasive bacteria, viruses
- Ubiquitinated cargo: p62/SQSTM1, OPTN, NDP52
| Partner |
Interaction Type |
Function |
| ATG7 |
Thioester bond |
E1 enzyme |
| ATG3 |
Thioester bond |
E2 enzyme |
| p62/SQSTM1 |
LIR binding |
Selective autophagy |
| OPTN |
LIR binding |
Selective autophagy |
| TRIM20 |
LIR binding |
Mitophagy receptor |
In AD:
- Autophagy impairment: LC3B2 lipidation reduced
- Amyloid-β clearance: Role in Aβ degradation
- Tau clearance: Autophagy-mediated tau removal
- Neuronal vulnerability: Autophagy defects
- Therapeutic potential: Autophagy enhancers
In PD:
- α-synuclein clearance: LC3B2-mediated autophagy
- Mitophagy: Mitochondrial quality control
- Leucine-rich repeat kinase 2: LRRK2 regulates autophagy
- GBA1 effects: Glucosylceramidase links to autophagy
In HD:
- Mutant huntingtin: Aggregate formation
- Autophagy induction: Clearance strategies
- Transcriptional dysregulation: LC3B2 expression affected
In ALS:
- Protein aggregate clearance: Impaired in ALS
- Autophagy receptors: p62, OPTN mutations
- TDP-43 pathology: Autophagy involvement
¶ Stroke and TBI
- Ischemia: Autophagy activation
- Reperfusion injury: Protective vs. detrimental
- Neuronal death: Autophagy dysregulation
| Approach |
Agent |
Status |
Mechanism |
| mTOR inhibitors |
Rapamycin |
Research |
Autophagy induction |
| AMPK activators |
Metformin |
Research |
Autophagy induction |
| TFEB activators |
Gene therapy |
Experimental |
Lysosomal biogenesis |
| Autophagy enhancers |
Trehalose |
Research |
mTOR-independent |
- Neuroprotection: Enhance aggregate clearance
- Disease modification: Target underlying pathology
- Combination therapy: With other approaches
- LC3B2 knockout mice: Viable with subtle defects
- GFP-LC3 mice: Monitor autophagy in vivo
- Disease models: Cross with AD/PD models
- Rapamycin treatment: Reduces pathology
- Trehalose administration: Promotes clearance
- Gene therapy: ATG genes delivery
- Kabeya Y, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes. J Cell Sci. 2004;117(Pt 13):2805-2812.
- Mizushima N, et al. Autophagy in mammalian development and differentiation. Nat Cell Biol. 2011;13(8):823-830.
- Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983-997.
- Jahreiss L, et al. The turnover of autophagic compartments. Autophagy. 2008;4(2):113-115.
- Kuma A, et al. The role of autophagy during the early neonatal starvation period. Nature. 2004;432(7020):1032-1036.
The study of Map1Lc3B2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kabeya Y, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes. J Cell Sci. 2004;117(Pt 13):2805-2812.
- Mizushima N, et al. Autophagy in mammalian development and differentiation. Nat Cell Biol. 2011;13(8):823-830.
- Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983-997.
- Jahreiss L, et al. The turnover of autophagic compartments. Autophagy. 2008;4(2):113-115.
- Kuma A, et al. The role of autophagy during the early neonatal starvation period. Nature. 2004;432(7020):1032-1036.